M161 M161 (Didanosine delayed release 250 mg)

Pill imprint M161 M161 has been identified as Didanosine delayed release 250 mg.

Didanosine is used in the treatment of hiv infection; nonoccupational exposure and belongs to the drug class nucleoside reverse transcriptase inhibitors (NRTIs). There is no proven risk in humans during pregnancy. Didanosine 250 mg is not a controlled substance under the Controlled Substance Act (CSA).

Didanosine delayed release

Imprint:

M161 M161

Strength:

250 mg

Color:

Yellow

Shape:

Capsule-shape

Availability:

Prescription only

Drug Class:

Nucleoside reverse transcriptase inhibitors (NRTIs)

Pregnancy Category:

B - No proven risk in humans

CSA Schedule:

Not a controlled drug

Manufacturer:

Mylan Pharmaceuticals Inc.

National Drug Code (NDC):

00378-8888

Inactive Ingredients:

ferrosoferric oxide
carboxymethylcellulose sodium
silicon dioxide
diethyl phthalate
gelatin
hypromelloses
methacrylic acid - methyl methacrylate copolymer (1:1)
propylene glycol
ferric oxide red
shellac
trisodium citrate dihydrate
sodium lauryl sulfate
sodium starch glycolate type A potato
magnesium silicate
titanium dioxide
ferric oxide yellow
potassium hydroxide

More info Print Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.